826 Differential effect of NKG2A blockade on peripheral and intra-tumoral CD8 T cell response induced by KISIMA – VSV-GP-TAg heterologous prime-boost vaccination

• Matteo Rossi,
• Elodie Belnoue,
• Susanna Carboni,
• Wilma Besson-Di Berardino,
• Erika Riva,
• Mati Moyat,
• Laetitia Devy-Dimanche

Affiliations

Matteo Rossi

Celyad Oncology, Mont-Saint-Guibert, Belgium

Elodie Belnoue

AMAL Therapeutics, Geneva, Switzerland

Susanna Carboni

AMAL Therapeutics, Geneva, Switzerland

Wilma Besson-Di Berardino

AMAL Therapeutics, Geneva, Switzerland

Erika Riva

1 Service of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland

Mati Moyat

1AMAL Therapeutics SA, Geneva, Switzerland

Laetitia Devy-Dimanche

1AMAL Therapeutics SA, Geneva, Switzerland